CytomX Therapeutics (CTMX) News Today $2.00 -0.13 (-5.90%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period CytomX Therapeutics Updates on CX-2051 Phase 1 StudyAugust 15, 2025 | msn.comFY2026 EPS Forecast for CytomX Therapeutics Cut by AnalystAugust 15, 2025 | marketbeat.comCytomX trial ongoing despite grade five event, says OppenheimerAugust 13, 2025 | msn.comHC Wainwright Issues Negative Outlook for CTMX EarningsAugust 13, 2025 | marketbeat.comCytomX Therapeutics Provides Update on CX-2051 Phase 1 StudyAugust 13, 2025 | globenewswire.comCytomX Therapeutics Earnings Call: Clinical Progress and Financial StrengthAugust 13, 2025 | msn.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comCytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comCytomX Therapeutics: Updated Outlook For Late 2025August 8, 2025 | seekingalpha.comCytomX (CTMX) Q2 Revenue Drops 26%August 7, 2025 | fool.comCytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7, 2025 | globenewswire.comCytomX Therapeutics (NASDAQ:CTMX) shareholders have earned a 79% return over the last yearAugust 3, 2025 | finance.yahoo.comCytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on ThursdayAugust 2, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Shares Pass Below 50 Day Moving Average - Here's What HappenedAugust 2, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Coverage Initiated at OppenheimerAugust 1, 2025 | marketbeat.comOppenheimer Initiates Coverage of CytomX Therapeutics (CTMX) with Outperform RecommendationAugust 1, 2025 | msn.comCytomX Therapeutics initiated with an Outperform at OppenheimerJuly 31, 2025 | msn.com2CTMX : Deep Dive Into CytomX Therapeutics Stock: Analyst Perspectives (4 Ratings)July 31, 2025 | benzinga.comCytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025July 31, 2025 | globenewswire.comCytomX (CTMX) Shares Promising Early Results for CRC Drug CandidateJuly 25, 2025 | finance.yahoo.comCytomX Therapeutics (NASDAQ:CTMX) Stock Price Passes Above 200-Day Moving Average - Time to Sell?July 10, 2025 | marketbeat.comCytomX Therapeutics, Inc. (CTMX) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comCytomX Therapeutics Inc. (CTMX) Stock Price Today - WSJJuly 2, 2025 | wsj.comCytomX Therapeutics (NASDAQ:CTMX) Shares Pass Above 50-Day Moving Average - Here's What HappenedJune 28, 2025 | marketbeat.comCongress Park Capital LLC Cuts Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX)June 20, 2025 | marketbeat.comTwo Sigma Investments LP Cuts Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)June 11, 2025 | marketbeat.comShort Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Grows By 82.0%June 1, 2025 | marketbeat.comMillennium Management LLC Grows Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX)June 1, 2025 | marketbeat.comTidal Investments LLC Buys 136,528 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)May 31, 2025 | marketbeat.comCytomX Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comFormidable Asset Management LLC Grows Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)May 27, 2025 | marketbeat.comPoint72 Asset Management L.P. Invests $2.73 Million in CytomX Therapeutics, Inc. (NASDAQ:CTMX)May 23, 2025 | marketbeat.comCytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)May 20, 2025 | benzinga.comTang Capital Management LLC Sells 500,000 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)May 20, 2025 | marketbeat.comEquities Analysts Set Expectations for CTMX Q2 EarningsMay 20, 2025 | marketbeat.comCytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic MelanomaMay 19, 2025 | globenewswire.comProsight Management LP Boosts Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)May 17, 2025 | marketbeat.comQ2 EPS Estimates for CytomX Therapeutics Cut by WedbushMay 16, 2025 | marketbeat.comBarclays Keeps Their Buy Rating on CytomX Therapeutics (CTMX)May 15, 2025 | theglobeandmail.comCytomX upgraded at H.C. Wainwright on trial data for cancer drugMay 15, 2025 | msn.comHC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX)May 15, 2025 | msn.comAfter pivots and layoffs, Peninsula drug company smells success, $100 million payoffMay 15, 2025 | bizjournals.comCytomX Therapeutics (NASDAQ:CTMX) Given "Outperform" Rating at WedbushMay 14, 2025 | marketbeat.comCytomX Therapeutics Sees Unusually Large Options Volume (NASDAQ:CTMX)May 14, 2025 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Announces Quarterly Earnings ResultsMay 14, 2025 | marketbeat.comCytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish?May 14, 2025 | seekingalpha.comCytomX Stock Hits 2-Month High After Upbeat Q1 Earnings, Promising Early Data For Cancer DrugMay 13, 2025 | msn.comCytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)May 12, 2025 | seekingalpha.comCytomX Therapeutics shares soar on positive cancer drug dataMay 12, 2025 | investing.comNano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data ReportMay 12, 2025 | benzinga.com Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address CTMX Media Mentions By Week CTMX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTMX News Sentiment▼0.000.71▲Average Medical News Sentiment CTMX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTMX Articles This Week▼02▲CTMX Articles Average Week Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Phibro Animal Health News Today Xeris Biopharma News Today CureVac News Today Enliven Therapeutics News Today Calliditas Therapeutics AB (publ) News Today Collegium Pharmaceutical News Today Intellia Therapeutics News Today Pharvaris News Today Structure Therapeutics News Today Tilray Brands News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTMX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access